FDA labels for these medications include warnings about the risk of dehydration and acute kidney injury, particularly during episodes of significant gastrointestinal illness
In this way, it can be an effective therapy for obesity. The Phase 2 clinical trial included 263 adults who had obesity or overweight, had at least one After 48 weeks, researchers found that all participants who received eloralintide experienced average weight loss between 9-20%, compared to only 0.4% weight loss in those on the placebo
Continuing the medication without medical guidance could risk a more severe reaction
Chen YM, Fan H, Huang J, Shi TS, Li WY, Wang CN, et al
and prebiotic fiber from certain legumes, whole grains, and fruits